
Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
Gilead to lay off 110+ employees at former Immunomedics HQ in another ding for its $21B deal
After a Phase III readout for the centerpiece of its $21 billion Immunomedics acquisition underwhelmed Wall Street, Gilead is bringing out the axe.
The California company is planning to lay off 114 staffers from its Morris Plains, NJ location in three waves later this year, according to a filing with the New Jersey Department of Labor. The layoffs are coming at the same site of Immunomedics’ former headquarters, a Gilead spokesperson told Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters